Difelikefalin in the Treatment of Hemodialysis Patients with Pruritus: a Systematic Review and Meta-analysis

Overview

Journal Front Pharmacol

Date 2024 Dec 23

PMID 39712488

Authors

Xiaoyue Cai

Guiming Wu

Yan Lin

Lichuan Yang

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Uremic pruritus is a persistent condition that is difficult to cure in patients with end-stage renal disease who are having regular dialysis. It is highly prevalent, and current therapies have limited effectiveness and can cause significant adverse effects. Several trials have provided evidence that difelikefalin can be an effective treatment for uremic pruritus, with few side responses. However, it is important to note that the available evidence is limited. This study collected published randomized controlled trials for systematic review and Meta-analysis, to explore the efficacy and safety of difelikefalin treating uremic pruritus and to provide evidence-based medical evidence for clinical treatment.

Methods: A systematic literature search was conducted in PubMed, EMBASE, Web of Science, the Cochrane Library Data from building libraries to 6 January 2024. We extracted data from eligible studies to analyze the efficacy and safety of difelikefalin in the treatment of hemodialysis patients with pruritus.

Results: This study comprised 9 trials with 4,118 people. The meta-analysis demonstrated that difelikefalin is more effective than placebo in treating uremic pruritus. Specifically, difelikefalin resulted in a greater improvement in WI-NRS scores of at least 3 points from baseline (OR = 1.98) and at least 4 points from baseline (OR = 1.94). Additionally, difelikefalin led to a decrease in the total score of the 5-D itch scale (MD = 1.56), a decrease in the skindex-10 scale score (MD = 4.92), and a decrease in the WI-NRS scale score (MD = 0.91).

Conclusion: Difelikefalin demonstrates significant efficacy in alleviating pruritus in individuals suffering from uremia. Althogh it has adverse events, they are mild.

References

Martin C, Clotet-Freixas S, Farragher J, Hundemer G . Have We Just Scratched the Surface? A Narrative Review of Uremic Pruritus in 2020. Can J Kidney Health Dis. 2020; 7:2054358120954024. PMC: 7573751. DOI: 10.1177/2054358120954024. View

Weiner D, Schaufler T, McCafferty K, Kalantar-Zadeh K, Germain M, Ruessmann D . Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis. Nephrol Dial Transplant. 2023; 39(7):1125-1137. PMC: 11210984. DOI: 10.1093/ndt/gfad245. View

Verduzco H, Shirazian S . CKD-Associated Pruritus: New Insights Into Diagnosis, Pathogenesis, and Management. Kidney Int Rep. 2020; 5(9):1387-1402. PMC: 7486142. DOI: 10.1016/j.ekir.2020.04.027. View

Cai X, Wu G, Zhang J, Yang L . Risk Factors for Acute Kidney Injury in Adult Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021; 8:719472. PMC: 8685316. DOI: 10.3389/fmed.2021.719472. View

Sukul N, Karaboyas A, Csomor P, Schaufler T, Wen W, Menzaghi F . Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients. Kidney Med. 2021; 3(1):42-53.e1. PMC: 7873756. DOI: 10.1016/j.xkme.2020.08.011. View

Aresi G, Rayner H, Hassan L, Burton J, Mitra S, Sanders C . Reasons for Underreporting of Uremic Pruritus in People With Chronic Kidney Disease: A Qualitative Study. J Pain Symptom Manage. 2019; 58(4):578-586.e2. DOI: 10.1016/j.jpainsymman.2019.06.010. View

Lu P, Yao X, Lin Y, Tzeng I, Lu P, Kuo K . Omega-3 fatty acids for uremic pruritus: A meta-analysis of randomized controlled trials. Tzu Chi Med J. 2022; 34(4):394-401. PMC: 9791849. DOI: 10.4103/tcmj.tcmj_221_21. View

Wala K, Szepietowski J . Difelikefalin in the Treatment of Chronic Kidney Disease-Associated Pruritus: A Systematic Review. Pharmaceuticals (Basel). 2022; 15(8). PMC: 9414620. DOI: 10.3390/ph15080934. View

Mettang T, Kremer A . Uremic pruritus. Kidney Int. 2014; 87(4):685-91. DOI: 10.1038/ki.2013.454. View

10.

Yosipovitch G, Awad A, Spencer R, Munera C, Menzaghi F . A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus. J Am Acad Dermatol. 2023; 89(2):261-268. DOI: 10.1016/j.jaad.2023.03.051. View

11.

Kuypers D, Claes K, Evenepoel P, Maes B, Vanrenterghem Y . A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant. 2004; 19(7):1895-901. DOI: 10.1093/ndt/gfh202. View

12.

Zhou Q, Zhang Z, Long S, Li W, Wang B, Liang N . Opioids in cancer: The κ‑opioid receptor (Review). Mol Med Rep. 2021; 25(2). PMC: 8674701. DOI: 10.3892/mmr.2021.12560. View

13.

Szepietowski J, Reich A, Schwartz R . Uraemic xerosis. Nephrol Dial Transplant. 2004; 19(11):2709-12. DOI: 10.1093/ndt/gfh480. View

14.

Spencer R, Munera C, Shram M, Menzaghi F . Assessment of the physical dependence potential of difelikefalin: Randomized placebo-controlled study in patients receiving hemodialysis. Clin Transl Sci. 2023; 16(9):1559-1568. PMC: 10499405. DOI: 10.1111/cts.13538. View

15.

Satti M, Arshad D, Javed H, Shahroz A, Tahir Z, Ahmed M . Uremic Pruritus: Prevalence and Impact on Quality of Life and Depressive Symptoms in Hemodialysis Patients. Cureus. 2019; 11(7):e5178. PMC: 6758963. DOI: 10.7759/cureus.5178. View

16.

Inan S, Cowan A . Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans. Handb Exp Pharmacol. 2020; 271:275-292. DOI: 10.1007/164_2020_420. View

17.

Fishbane S, Wen W, Munera C, Lin R, Bagal S, McCafferty K . Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program. Kidney Med. 2022; 4(8):100513. PMC: 9418597. DOI: 10.1016/j.xkme.2022.100513. View

18.

Xue G, Yuan H, Fan D, Yang Y, Ma C, Liu J . Efficacy and safety of difelikefalin in the treatment of hemodialysis patients with pruritus: A meta-analysis and systematic review. Clin Nephrol. 2024; 101(4):155-163. DOI: 10.5414/CN111169. View

19.

Narita I, Tsubakihara Y, Takahashi N, Ebata T, Uchiyama T, Marumo M . Difelikefalin for Hemodialysis Patients with Pruritus in Japan. NEJM Evid. 2024; 2(11):EVIDoa2300094. DOI: 10.1056/EVIDoa2300094. View

20.

Makar M, Smyth B, Brennan F . Chronic Kidney Disease-Associated Pruritus: A Review. Kidney Blood Press Res. 2021; 46(6):659-669. DOI: 10.1159/000518391. View